Welcome to the ATGesundheit Institute
ATGesundheit Institute consults with individuals undergoing investigational oncolytic virus & cancer immunotherapy treatment to improve clinical outcomes and quality of life. Oncolytic virus therapy combined with other therapies is a promising approach with potential to extend survival time and to improve quality of life.
Please read our published research:
Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series, Frontiers in Oncology
Published March 2025: Oncolytic Virotherapy for Relapsed, IDH-Mutant, Grade 3 Astrocytoma: A New Promising Approach – A Case Report, Frontiers in Oncology.
In this video, Dr. Gesundheit explains how oncolytic viruses work.
Dr. Beni Gesundheit, MD PhD
Scientific Advisor,
Rapo Yerape BH Ltd.
Dr. Hüseyin Sahinbas, MD
Physician,
Praxis für Hyperthermie
OV Research
The ability to genetically engineer oncolytic viruses (OV) to minimize side effects and improve the selective targeting of tumor cells may open up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system may help guide the development of new strategies.
EDITED BY: Benjamin Gesundheit and Joshua P. Rosenzweig
PUBLISHED IN: Frontiers in Oncology and Frontiers in Immunology
FAQ
Oncolytic virus (OV) immunotherapy utilizes selected viruses to target tumor cell types without harming healthy tissue. Their selectivity is attributed to different biological features of the surface of cancer tumor cells that are absent in normal human cells. Once the infected tumor cell is destroyed by OVs, the amplified OVs can infect and target adjacent tumor cells, eventually eliminating the entire tumor mass.
OV provides a direct tumor-killing (oncolytic) effect and a parallel activation of the patient’s immune system against tumor cells (immunotherapy). Since 2010 immunotherapy has been revolutionizing oncology treatment and has provided new biotechnology products for standard clinical practice. These products have included the first licensed OV therapy indicated for the treatment of melanoma (2015), which stands as proof of concept for the entire OV therapy field.
People have experienced minimal side effects. Fever is a side effect that is also a sign of a successful immune response. When necessary fever can be prevented or reduced using standard analgesics. No long-term side effects have been reported.
OV treatments are usually scheduled for between 2-6 weeks. The time interval between treatments depends on the status of the illness and one’s highly individual immune response. Quarterly evaluations after 12-18 months of intense treatment is important to monitor health and look for signs of cancer.
ATGesundheit Institute consultation fee is € 200 per hour. The treating center will provide you with a list of their fees.
The FET PET scan is very important for the doctor, as it helps them decide the best course of action or treatment for the patient.
This medical test uses a substance called Fluoroethyl Tyrosine (FET) to show how amino acids move in the body. It is a type of Positron Emission Tomography (PET) scan that can help localize tumors with higher sensitivity than other imaging techniques. This information can contribute to therapy planning, tumor control, and follow-up.
During the test, the FET substance is injected into the blood and moves throughout the body. It attaches to areas where there is active disease, such as tumors, and can be detected by PET/CT (Computer Tomography) scanners. These machines can show how much of the FET substance is in the brain and where it is located.
Unlike MRI (Magnetic Resonance Imaging), that mostly shows anatomical structures, FET PET can give additional information on the functional aspect of tissues at a molecular level.
Questions?
Please take the opportunity to contact us either with a general query or to begin the application process.